Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
Google Scholar
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).
Google Scholar
Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).
Google Scholar
Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619–1629 (2022).
Google Scholar
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).
Google Scholar
Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355–1360 (2018).
Google Scholar
Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
Google Scholar
Gong, N. Q. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607–625 (2024).
Google Scholar
Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298–312 (2021).
Google Scholar
Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).
Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043–1052 (2020).
Google Scholar
Wang, C. et al. Oncolytic mineralized bacteria as potent locally administered immunotherapeutics. Nat. Biomed. Eng. 8, 561–578 (2024).
Zhang, Y. B. et al. Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy. Nat. Nanotechnol. 18, 1364–1374 (2023).
Google Scholar
Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
Google Scholar
Aaes, T. L. & Vandenabeele, P. The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death Differ. 28, 843–860 (2021).
Google Scholar
Bedoui, S., Herold, M. J. & Strasser, A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat. Rev. Mol. Cell Biol. 21, 678–695 (2020).
Google Scholar
Meier, P. et al. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat. Rev. Cancer 24, 299–315 (2024).
Chen, B. et al. A pyroptosis nanotuner for cancer therapy. Nat. Nanotechnol. 17, 788–798 (2022).
Google Scholar
Chen, B., Zhang, Q., Gao, J. & Wang, Y. Control cell death by endosomal trafficking of proton transistor nanophotosensitizers. Life Med. 1, 264–266 (2022).
Google Scholar
Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543–557 (2009).
Google Scholar
Zhao, R. et al. A pH-responsive nanoparticle library with precise pH tunability by co-polymerization with non-ionizable monomers. Angew. Chem. Int. Ed. 61, e202200152 (2022).
Google Scholar
Wang, Y. et al. Digitization of endocytic pH by hybrid ultra-pH-sensitive nanoprobes at single-organelle resolution. Adv. Mater. 29, 1603794 (2017).
Wang, Z. et al. pH-amplified CRET nanoparticles for in vivo imaging of tumor metastatic lymph nodes. Angew. Chem. Int. Ed. 60, 14512–14520 (2021).
Google Scholar
Tang, M. et al. pH-gated nanoparticles selectively regulate lysosomal function of tumour-associated macrophages for cancer immunotherapy. Nat. Commun. 14, 5888 (2023).
Google Scholar
Akishiba, M. et al. Cytosolic antibody delivery by lipid-sensitive endosomolytic peptide. Nat. Chem. 9, 751–761 (2017).
Google Scholar
Teo, W. et al. Nile Red fluorescence spectroscopy reports early physicochemical changes in myelin with high sensitivity. Proc. Natl Acad. Sci. USA 118, e2016897118 (2021).
Fuchs, Y. & Steller, H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat. Rev. Mol. Cell Biol. 16, 329–344 (2015).
Google Scholar
Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).
Google Scholar
Adamik, J. & Butterfield, L. H. What’s next for cancer vaccines. Sci. Transl. Med. 14, eabo4632 (2022).
Google Scholar
Guo, Y. et al. In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses. Nat. Commun. 13, 6534 (2022).
Google Scholar
Chao, Y. et al. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses. Nat. Biomed. Eng. 2, 611–621 (2018).
Google Scholar
Li, W. et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 10, 3349 (2019).
Google Scholar
Shekarian, T. et al. Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Sci. Transl. Med. 11, eaat5025 (2019).
Xia, H. et al. A pH-/enzyme-responsive nanoparticle selectively targets endosomal toll-like receptors to potentiate robust cancer vaccination. Nano Lett. 22, 2978–2987 (2022).
Google Scholar
